Veru Inc. - Common Stock (VERU)
3.5000
-0.1500 (-4.11%)
NASDAQ · Last Trade: Oct 29th, 10:04 PM EDT
Detailed Quote
| Previous Close | 3.650 |
|---|---|
| Open | 3.670 |
| Bid | 2.800 |
| Ask | 2.970 |
| Day's Range | 3.500 - 3.745 |
| 52 Week Range | 2.640 - 14.20 |
| Volume | 268,487 |
| Market Cap | 512.34M |
| PE Ratio (TTM) | -50.00 |
| EPS (TTM) | -0.1 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 142,672 |
Chart
About Veru Inc. - Common Stock (VERU)
Veru Inc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of diseases, particularly in the areas of oncology and urology. The company is engaged in the research and development of novel drug candidates aimed at addressing unmet medical needs, with a strong emphasis on advancing therapies for prostate cancer and other challenging health conditions. Veru is also involved in the production of specialty pharmaceutical products, showcasing its commitment to improving patient outcomes through scientific innovation and rigorous clinical trials. Read More
News & Press Releases
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · October 29, 2025
Via Benzinga · October 29, 2025
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
Via Benzinga · September 25, 2025

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · May 28, 2025

Via Benzinga · May 28, 2025
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · April 1, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · April 1, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · January 27, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · January 27, 2025

Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · January 27, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · January 27, 2025

Via Benzinga · January 27, 2025

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.
Via Benzinga · January 27, 2025

Via Benzinga · January 27, 2025

Veru jumps after selling FC2 Female Condom business for $18 million, reducing workforce by 90%.
Via Benzinga · December 31, 2024

Via Benzinga · October 11, 2024

Via Benzinga · October 10, 2024

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END
Via FinancialNewsMedia · August 6, 2024

